KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
暂无分享,去创建一个
Ash A. Alizadeh | K. Ramchandran | J. Shrager | J. Chabon | Emily G. Hamilton | D. Kurtz | E. Moding | H. Stehr | B. Nabet | Diego Almanza | Young-Jun Jeon | Monica Nesselbush | C. Yoo | R. Ko | J. Neal | H. Wakelee | B. Loo | C. Kunder | M. Berry | M. Diehn | P. Maxim | Siyeon Rhee | J. Shin | M. Binkley | L. Backhus | M. Xiang | M. Das | S. Padda | Linda Gojenola | N. Lui | S. G. Owen
[1] K. Forster,et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Kwok-Kin Wong,et al. Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. , 2019, Cell metabolism.
[3] G. Ciliberto,et al. Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] K. Ramchandran,et al. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.
[5] R. Deberardinis,et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. , 2019, Cancer research.
[6] David A. Knowles,et al. Clinically-relevant cell type cross-talk identified from a human lung tumor microenvironment interactome , 2019, bioRxiv.
[7] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[8] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[10] Tomas Kron,et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. , 2019, The Lancet. Oncology.
[11] Ryan L. Collins,et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes , 2019, bioRxiv.
[12] Mary A Davis,et al. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice , 2019, International journal of radiation biology.
[13] P. Adriaensens,et al. Glutamine Addiction and Therapeutic Strategies in Lung Cancer , 2019, International journal of molecular sciences.
[14] C. Paweletz,et al. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. , 2018, Cancer discovery.
[15] M. V. van Gisbergen,et al. Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. , 2018, Lung cancer.
[16] S. Kalnicki,et al. Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.
[17] K. Sutherland,et al. “Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway , 2018, Cell cycle.
[18] J. Szustakowski,et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.
[19] T. Graeber,et al. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. , 2018, Cancer cell.
[20] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[21] Akiko Seki,et al. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells , 2018, The Journal of experimental medicine.
[22] Ash A. Alizadeh,et al. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma , 2018, Clinical Cancer Research.
[23] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[24] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[25] E. Yorke,et al. PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT) , 2017, Clinical and translational radiation oncology.
[26] Julian C. Hong,et al. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] W. Curran,et al. Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy , 2017, Cancer.
[28] Francisco J. Sánchez-Rivera,et al. Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.
[29] Ash A. Alizadeh,et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. , 2017, Cancer discovery.
[30] H. Stehr,et al. ERBB2‐Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] S. Kalnicki,et al. 18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. , 2017, International journal of radiation oncology, biology, physics.
[32] D. Dziedzic,et al. Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer. , 2016, Clinical lung cancer.
[33] Angela N. Brooks,et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.
[34] Joe Y. Chang,et al. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.
[35] Yiguo Zhang,et al. Molecular and cellular basis for the unique functioning of Nrf1, an indispensable transcription factor for maintaining cell homoeostasis and organ integrity. , 2016, The Biochemical journal.
[36] Gabriela Alexe,et al. Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.
[37] J. Sonke,et al. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[38] Robert Patro,et al. RapMap: a rapid, sensitive and accurate tool for mapping RNA-seq reads to transcriptomes , 2015, bioRxiv.
[39] H. Date,et al. Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non–Small-Cell Lung Cancer: Importance of Salvage Surgery , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[41] P. Catalano,et al. Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. , 2015, Clinical lung cancer.
[42] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[43] Jukka Westermarck,et al. ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays , 2014, PloS one.
[44] Bridgid E Hast,et al. Molecular and Cellular Pathobiology Cancer-derived Mutations in Keap1 Impair Nrf2 Degradation but Not Ubiquitination , 2022 .
[45] F. Galateau-Sallé,et al. Impact of Delay to Cryopreservation on RNA Integrity and Genome-Wide Expression Profiles in Resected Tumor Samples , 2013, PloS one.
[46] J. Mesirov,et al. Integrative radiogenomic profiling of squamous cell lung cancer. , 2013, Cancer research.
[47] P. Massion,et al. SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival , 2012, Clinical Cancer Research.
[48] Suresh Senan,et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.
[49] C. Bhamidipati,et al. Tumor recurrence after complete resection for non-small cell lung cancer. , 2012, The Annals of thoracic surgery.
[50] Benjamin Movsas,et al. Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[51] R. Whyte,et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. , 2010, International journal of radiation oncology, biology, physics.
[52] L. Hlatky,et al. Ionizing radiation activates the Nrf2 antioxidant response. , 2010, Cancer research.
[53] S. Biswal,et al. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. , 2010, Antioxidants & redox signaling.
[54] A. Gazdar,et al. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.
[55] Maria Werner-Wasik,et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[56] J. Herman,et al. Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer , 2006, PLoS medicine.
[57] Angel Ortega,et al. Glutathione in Cancer Biology and Therapy , 2006, Critical reviews in clinical laboratory sciences.